1407632-07-8
Chemical Structure
PSB-12054
- CAS No.: 1407632-07-8
- Formula:C20H15NO3
- Molecular Weight:317.34
IUPAC Name: benzyl 10H-phenoxazine-10-carboxylate
InChIKey: KGVCOYMLGBNCDW-UHFFFAOYSA-N
SMILES: O=C(OCC=1C=CC=CC1)N2C=3C=CC=CC3OC=4C=CC=CC42
Biological Activity: PSB-12054 is a P2X4 receptor antagonist with IC50 values of 0.19 μM, 2.10 μM and 1.77 μM against human, rat and mouse receptors, respectively, and exhibits selectivity over other human P2X receptor subtypes. PSB-12054 inhibits ATP-induced calcium influx, suppresses shear stress-induced transverse Ca2+ wave generation, and elevates basal Ca2+ levels in rat atrial myocytes. PSB-12054 binds to the 5-HT2B receptor. PSB-12054 can be used in research related to neuropathic pain, traumatic brain injury, cerebral ischemia and spinal cord injury[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
PSB-12054 | 98.94% | PSB-12054 is a P2X4 receptor antagonist with IC50 values of 0.19 μM, 2.10 μM and 1.77 μM against human, rat and mouse receptors, respectively, and exhibits selectivity over other human P2X receptor subtypes. PSB-12054 inhibits ATP-induced calcium influx, suppresses shear stress-induced transverse Ca2+ wave generation, and elevates basal Ca2+ levels in rat atrial myocytes. PSB-12054 binds to the 5-HT2B receptor. PSB-12054 can be used in research related to neuropathic pain, traumatic brain injury, cerebral ischemia and spinal cord injury. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Hernandez-Olmos V, et al. N-substituted phenoxazine and acridone derivatives: structure-activity relationships of potent P2X4 receptor antagonists. Journal of medicinal chemistry. 2012 Nov 26;55(22):9576-88. [Content Brief]
- [2]. Le QA, et al. Distinct shear-induced Ca signaling in the left and right atrial myocytes: Role of P2 receptor context. Journal of molecular and cellular cardiology. 2020 Jun;143:38-50.
- [3]. Li B, et al. Molecular mechanism underlying the subtype-selectivity of competitive inhibitor NF110 and its distinct potencies in human and rat P2X3 receptors. Sci Bull (Beijing). 2018 Dec 30;63(24):1616-1625.
- [4]. Adamiak M, et al. The P2X4 purinergic receptor has emerged as a potent regulator of hematopoietic stem/progenitor cell mobilization and homing-a novel view of P2X4 and P2X7 receptor interaction in orchestrating stem cell trafficking. Leukemia. 2022 Jan;36(1):248-256.
